<DOC>
	<DOC>NCT00211705</DOC>
	<brief_summary>To evaluate the primary preventive effect of low-dose pravastatin against coronary heart disease (CHD) in Japanese hypercholesterolemic patients.</brief_summary>
	<brief_title>Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)</brief_title>
	<detailed_description>MEGA Study is the first prospective, randomized, controlled trial conducted in Japan to evaluate the primary preventive effect of pravastatin against CHD in daily clinical practice. Because the dose of pravastatin used in the MEGA Study was 10–20 mg/day, which is consistent with the approved doses in Japan and lower than the doses used in previous large-scale clinical trials.</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>TC:220～270mg/dl Male: 4070 years old/ female: postmenopausal70 years old &lt;40kg in weight FH History of CHD(angina, MI, postPTCA/CABG, etc.) History of CVA(stroke, TIA, etc.) Underlying malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>coronary heart disease</keyword>
	<keyword>prevention</keyword>
	<keyword>stroke</keyword>
	<keyword>pravastatin</keyword>
</DOC>